Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29483938 | 1.00 | PRKCB (0.70) | PRKCBPAK4 | |
| Ethyl Acetate SCHEMBL3327751 | 0.92 | PRKCB (0.61) | PRKCBPAK4 | |
| SCHEMBL3326904 | 0.85 | PRKCB (0.65) | PRKCBPAK4 | |
| SCHEMBL22217131 | 0.84 | PRKCB (0.71) | PRKCBPAK4 | |
| SCHEMBL16627163 | 0.82 | PRKCB (0.75) | PRKCB | |
| SCHEMBL16624981 | 0.80 | PRKCB (0.62) | PRKCBPAK4 | |
| SCHEMBL3326156 | 0.80 | PRKCB (1.00) | PRKCB | |
| SCHEMBL3325766 | 0.78 | PRKCB (0.69) | PRKCBPAK4 | |
| SCHEMBL19200827 | 0.77 | PRKCB (1.00) | PRKCB | |
| SCHEMBL3323117 | 0.77 | PRKCB (1.00) | PRKCB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170217991-A1 | NOVEL 3-AMINO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H,6H) CARBALDEHYDE DERIVATIVES | PFIZER INC. | 2017-08-03 | — | — | US | disclosed |
| US-20170217991-A1 | NOVEL 3-AMINO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H,6H) CARBALDEHYDE DERIVATIVES | PFIZER INC. | 2017-08-03 | — | — | US | disclosed |
| US-9518060-B2 | Substituted pyrrolo[3,4-c]pyrazoles as PKC kinase inhibitors | PFIZER INC. (US) | 2016-12-13 | — | — | US | disclosed |
| US-20150099743-A1 | NOVEL N-PYRIMIDIN-4-YL-3-AMINO-PYRROLO[3,4-C]PYRAZOLE DERIVATIVES AS PKC KINASE INHIBITORS | PFIZER INC. | 2015-04-09 | — | — | US | disclosed |
| US-8877761-B2 | N-pyrimidin-4-yl-3-amino-pyrrolo[3,4-c]pyrazole derivatives as PKC kinase inhibitors | PFIZER INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-8877761-B2 | N-pyrimidin-4-yl-3-amino-pyrrolo[3,4-c]pyrazole derivatives as PKC kinase inhibitors | PFIZER INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20120202809-A1 | NOVEL N-PYRIMIDIN-4-YL-3-AMINO-PYRROLO[3,4-C]PYRAZOLE DERIVATIVES AS PKC KINASE INHIBITORS | PFIZER INC. | 2012-08-09 | — | — | US | disclosed |
| US-8183255-B2 | N-pyrimidin-4-yl-3-amino-pyrrolo[3,4-c]pyrazole derivatives as PKC kinase inhibitors | PFIZER, INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20100130501-A1 | NOVEL 3-AMINO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H, 6H) CARBALDEHYDE DERIVATIVES | PFIZER INC. | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217991-A1 | NOVEL 3-AMINO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H,6H) CARBALDEHYDE DERIVATIVES | INSR, IAPP, GPR119 | PRKCB 1116/4885PAK4 3757/4885 |
| US-20100130501-A1 | NOVEL 3-AMINO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H, 6H) CARBALDEHYDE DERIVATIVES | DPP3, IAPP, GPR119 | PRKCB 990/4885PAK4 3900/4885 |
| US-20120202809-A1 | NOVEL N-PYRIMIDIN-4-YL-3-AMINO-PYRROLO[3,4-C]PYRAZOLE DERIVATIVES AS PKC KINASE INHIBITORS | PRKCB, PRKCA, PRKCE | PRKCB 1/4885PAK4 623/4885 |
| US-20150099743-A1 | NOVEL N-PYRIMIDIN-4-YL-3-AMINO-PYRROLO[3,4-C]PYRAZOLE DERIVATIVES AS PKC KINASE INHIBITORS | PRKCB, PRKCA, PRKCQ | PRKCB 1/4885PAK4 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.